1. 1) U.S. Food and Drug Administration. “Fact sheet for healthcare providers: emergency use authorization for Paxlovid™.” 2022: 〈https://www.fda.gov/media/155050/download〉, cited 14 April, 2022.
2. 2) Marzolini C., Kuritzkes D. R., Marra F., Boyle A., Gibbons S., Flexner C., Pozniak A., Boffito M., Waters L., Burger D., Back D. J., Khoo S., Clin. Pharmacol. Ther., 112, 1191–1200 (2022).
3. 3) Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V. M., Damle B., Simón-Campos A., Pypstra R., Rusnak J. M., N. Engl. J. Med., 386, 1397–1408 (2022).
4. 4) National Institutes of Health. “Therapeutic management of nonhospitalized adults with COVID-19.” 2022: 〈https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/〉, cited 30 December, 2022.
5. 5) Marzolini C., Gibbons G., Khoo S., Back D., J. Antimicrob. Chemother., 71, 1755–1758 (2016).